Physician profile
Gregory C Warner
NPI 1699810689
$4,983.74
in general payments reported to CMS, 2019-2025
23 companies · $950 in 2025
The $950 reported for 2025 was more than what 76% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $315 · 2021: $363 · 2022: $665 · 2023: $1,049 · 2024: $1,034 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.21 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,877.49 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,312.87 | 2019-2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $265.74 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $198.69 | 2021-2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $182.32 | 2019-2024 | Breztri, Airsupra, Tezspire |
| Inari Medical, INC. | $149.38 | 2022 | |
| Abiomed | $144.70 | 2023 | Impella |
| United Therapeutics Corporation | $106.07 | 2022-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $104.44 | 2025 | Yupelri |
| Intuitive Surgical, INC. | $89.76 | 2023 | Da Vinci Surgical System |
| Insmed, INC. | $79.55 | 2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $75.84 | 2025 | Prolastin-C Liquid |
| Tanabe Pharma America, INC. | $70.86 | 2023-2025 | Radicava |
| Biogen, INC. | $52.33 | 2023-2024 | Tysabri, Vumerity |
| Philips North America LLC | $51.45 | 2019-2025 | Vest Therapy Und |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.05 | 2023 | Recarbrio, Zerbaxa, Zinplava |
| Genzyme Corporation | $38.01 | 2019-2023 | |
| Genentech USA, INC. | $36.37 | 2019 | |
| Amgen INC. | $29.29 | 2021-2023 | Tezspire |
| Verona Pharma, INC. | $25.08 | 2025 | Ohtuvayre |
| Smith+Nephew, INC. | $21.34 | 2025 | Collagenase Santyl |
| Takeda Pharmaceuticals U.S.A., INC. | $21.04 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.